Rheumatology

Patients receiving 6MP prophylaxis experienced significantly reduced incidence of arthromyalgia and Health Assessment Questionnaire worsening of 22% or increase of .25.

In patients with systemic lupus erythematosus receiving rituximab and belimumab, Black and Indo-Asian patients were less likely to obtain major clinical response.

An analysis of data from the APPLE study provides insight into the heterogeneity that exists within pediatric systemic lupus erythematosus patients.

An analysis of 100 week data from the KEEPsAKE 1 and 2 trials presented at EULAR 2023 offers insight into the long-term effects of risankizumab use in people with psoriatic arthritis.

An analysis of patient-reported outcomes data from the MIRROR trial offers insight into the effects of pegloticase plus methotrexate on quality of life and various disease activity indices.

New data from EULAR 2023 offers a comparison of the levels of vascular inflammation among patients with psoriatic arthritis relative to healthy controls.

An analysis of patient data from Sweden and Norway detail the impact of achieving remission with methotrexate or TNF inhibitors on risk of acute coronary syndrome in patients with rheumatoid arthritis.

An analysis of NHANES data from 2011-2018 presented at EULAR 2023 offers an overview of the disproportionate growth in gout burden for Asian Americans relative to their White counterparts.

Data from the BE VITAL OLE study, which included patients from the BE COMPLETE and BE OPTIMAL studies, suggests the benefits of bimekizumab in patients with psoriatic arthritis with inadequate response or intolerance to TNF inhibitors were sustained for up to 52 weeis.

The disparities compelled them to launch Determi-Nation, which utilizes healthcare providers, advocates, and patients within the psoriatic disease community to co-create solutions that address the observed inequities.

Leveraging data from the 2020 UPLIFT survey, investigators offer an overview of the quality of life and treatment satisfaction among people with psoriasis and psoriatic arthritis in the US.

The long-term extension SENSCIS-ON trial shows patients receiving nintedanib over 3 years were not at significantly greater risk of serious adverse events or outcomes.

A study leveraging DoD data provides a comprehensive overview of clinical features, treatment choices, and outcomes of patients with immune mediated necrotizing myopathy relative to those of patients with other idiopathy inflammatory myopathies.

At the 12-month mark, 52% of patients in the axSpA cohort and 76% of those in the IBD cohort achieved clinical remission.

An analysis of data obtained from urine samples in the MUSE and TULIP-1 trial sheds new light on the clinical utility of the RAIL score for identifying disease activity and treatment responders in SLE patients with and without lupus nephritis, respectively

CCR East 2023 data show ixekizumab bettered adalimumab on measures of joint pain and quality of life in patients with PsA and concomitant nail plus DIP involvement.

An analysis of Medcare claims data offers clinicians an overview or the effectiveness of sarilumab and tocilizumab in second- and third-line polymyalgia rheumatica treatments relative to conventional immunomodulators, such as methotrexate or azathioprine.

Post-hoc analysis from DISCOVER-2 show patients who achieve a clinical response by week 8 generally go on to see quality-of-life improvements past 1 year.

An analysis of data from the National Inpatient Sample offers an overview of risk for adverse delivery outcomes associated with Takayasu arteritis among a real-world cohort of US-based patients.

An analysis of 11 late-stage clinical trials shows guselkumab provides a consistent and comparable safety profile to placebo in treated patients.

Therapies including biologics and corticosteroids were more frequently used among patients with rheumatoid arthritis and lupus who developed severe COVID-19.

New data from CCR East show Black and Hispanic patients with PsA are significantly more likely to report worse health-related quality of life than White patients.

An analysis of more than 250 pregnancies among women with SLE from the Hopkins Lupus Cohort provides insight into risk of adverse pregnancy outcomes based on serum 25-hydroxy vitamin D levels using real-world data.

An analysis of the National Inpatient Sample offers a deep dive into the risk of adverse outcomes associated with presence of polymyositis or dermatomyositis among patients with congestive heart failure.

Pooled data from the phase 3 TULIP program offer additional insight into the effects of anifrolumab use in people with moderate-to-severe systemic lupus erythematosus.

Patients with psoriatic arthritis and/or psoriasis reported improved BMI and HbA1C after 6 months of apremilast—with pronounced benefit among patients with obesity.

A comparison of monotherapy biologic or targeted synthetic DMARDs initiated in naive patients show each are beneficial for rheumatoid arthritis.

Data from the UPLIFT study show patients with psoriatic arthritis and their physicians see eye-to-eye on most subjects—except for treatment goals.

Data from an analysis of kidney biopsies from the AURORA 2 trial presented at CCR East 2023 offer new insight into the long-term histological impact of voclosporin use on renal function in patients with lupus nephritis.